Literature DB >> 16691128

C677T and A1298C methylenetetrahydrofolate reductase gene polymorphisms in schizophrenia, bipolar disorder and depression: a meta-analysis of genetic association studies.

Elias Zintzaras1.   

Abstract

A meta-analysis of the previous studies of allelic association between schizophrenia, bipolar disorder and depression with the C677T and A1298C polymorphisms of the methylenetetrahydrofolate reductase (MTHFR) gene was carried out. Attention was paid to genetic differences in ancestral groups. Ten studies of the C677T MTHFR polymorphism and schizophrenia were included, along with four studies with the A1298C MTHFR polymorphism and schizophrenia. Four association studies of the C677T MTHFR polymorphism with bipolar disorder, and five studies of the C677T base pair change with depression were included. The studies contained Caucasian and east Asian samples. For schizophrenia, the main analysis for investigating the association of the C677T allele T and the risk of developing schizophrenia relative to the allele C showed lack of heterogeneity (P = 0.22, I(2) = 24%) between samples. In these samples, the fixed effects odds ratio was marginally significant [odds ratio 1.13 (95% confidence interval, 1.04-1.23)]. In an analysis of subgroups, the odds ratio were not significant for the Caucasian sample [random effects odds ratio 1.14 (0.95-1.36) and fixed effects odds ratio 1.13 (1.00-1.27)](P = 0.14, I(2) = 43%) and in Asians [random effects odds ratio 1.15 (0.98-1.35) and fixed effects odds ratio 1.15 (1.01-1.31)] (P = 0.19, I(2) = 37). The recessive model for allele T produced significant results in the main analysis [fixed effects odds ratio 1.32 (1.12-1.56)] in east Asians [fixed effects odds ratio 1.45 (1.13-1.85)] and female participants [fixed effects odds ratio 1.70 (1.07-2.71)], whereas for Caucasians the results were nonsignificant. For the A1298C polymorphism, in the main analysis the allele frequency difference between C and A, and the dominant model for allele C produced marginally significant associations [fixed effects odds ratio 1.16 (1.03-1.31) and fixed effects odds ratio 1.19 (1.02-1.40), respectively]. In bipolar disorder, overall, there was no significant association between either allele of the C677T polymorphism and the risk of developing bipolar disorder. Only in the east Asian population was the C677T association of marginal significance, with fixed effects odds ratio 1.23 (1.00-1.52). No sources of potential bias were found in the selected studies. The meta-analysis results suggested that east Asians have a greater genetic risk from the MTHFR gene in developing schizophrenia and depression, and that the genetic effects in bipolar disorder and depression are different. A further exploration of the involvement of the MTHFR gene in the susceptibility to schizophrenia and affective disorders, with a greater number of studies with larger sample sizes, however, are needed to fully establish the role of the MTHFR gene.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16691128     DOI: 10.1097/01.ypg.0000199444.77291.e2

Source DB:  PubMed          Journal:  Psychiatr Genet        ISSN: 0955-8829            Impact factor:   2.458


  35 in total

1.  Maternal gene polymorphisms involved in folate metabolism and risk of Down syndrome offspring: a meta-analysis.

Authors:  Elias Zintzaras
Journal:  J Hum Genet       Date:  2007-10-13       Impact factor: 3.172

2.  Trends in meta-analysis of genetic association studies.

Authors:  Elias Zintzaras; Joseph Lau
Journal:  J Hum Genet       Date:  2007-12-12       Impact factor: 3.172

3.  Methylenetetrahydrofolate reductase gene polymorphism as a risk factor for diabetic nephropathy: a meta-analysis.

Authors:  Elias Zintzaras; Katrin Uhlig; George N Koukoulis; Afroditi A Papathanasiou; Ioannis Stefanidis
Journal:  J Hum Genet       Date:  2007-09-06       Impact factor: 3.172

4.  A meta-analysis of genotypes and haplotypes of methylenetetrahydrofolate reductase gene polymorphisms in acute lymphoblastic leukemia.

Authors:  Elias Zintzaras; Theocharis Koufakis; Panayiotis D Ziakas; Paraskevi Rodopoulou; Stavroula Giannouli; Michael Voulgarelis
Journal:  Eur J Epidemiol       Date:  2006-08-09       Impact factor: 8.082

5.  Targeted insertion of two Mthfr promoters in mice reveals temporal- and tissue-specific regulation.

Authors:  Laura Pickell; Qing Wu; Xiao-Ling Wang; Daniel Leclerc; Hana Friedman; Alan C Peterson; Rima Rozen
Journal:  Mamm Genome       Date:  2011-07-19       Impact factor: 2.957

6.  Methylenetetrahydrofolate reductase (MTHFR) polymorphism susceptibility to schizophrenia and bipolar disorder: an updated meta-analysis.

Authors:  Cai-Yun Hu; Zhen-Zhong Qian; Feng-Feng Gong; Shan-Shan Lu; Fang Feng; Yi-Le Wu; Hui-Yun Yang; Ye-Huan Sun
Journal:  J Neural Transm (Vienna)       Date:  2014-06-18       Impact factor: 3.575

7.  A Hybrid Machine Learning Method for Fusing fMRI and Genetic Data: Combining both Improves Classification of Schizophrenia.

Authors:  Honghui Yang; Jingyu Liu; Jing Sui; Godfrey Pearlson; Vince D Calhoun
Journal:  Front Hum Neurosci       Date:  2010-10-25       Impact factor: 3.169

8.  The role of MTHFR gene in multiple myeloma.

Authors:  Elias Zintzaras; Stavroula Giannouli; Paraskevi Rodopoulou; Michael Voulgarelis
Journal:  J Hum Genet       Date:  2008-03-19       Impact factor: 3.172

9.  Association of MTHFR C677T polymorphism with schizophrenia and its effect on episodic memory and gray matter density in patients.

Authors:  Yanling Zhang; Hao Yan; Lin Tian; Fang Wang; Tianlan Lu; Lifang Wang; Jun Yan; Qi Liu; Lan Kang; Yanyan Ruan; Dai Zhang; Weihua Yue
Journal:  Behav Brain Res       Date:  2013-01-12       Impact factor: 3.332

10.  Metabolic syndrome and insulin resistance in schizophrenia patients receiving antipsychotics genotyped for the methylenetetrahydrofolate reductase (MTHFR) 677C/T and 1298A/C variants.

Authors:  Vicki L Ellingrod; Del D Miller; Stephan F Taylor; Jessica Moline; Timothy Holman; Jane Kerr
Journal:  Schizophr Res       Date:  2007-10-31       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.